Diplomat Pharmacy (NYSE:DPLO) issued an update on its FY 2019 earnings guidance on Friday morning. The company provided EPS guidance of $-0.5-0.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.61. The company issued revenue guidance of $4.7-5 billion, compared to the consensus revenue estimate of $5.45 billion.
NYSE DPLO opened at $6.42 on Friday. Diplomat Pharmacy has a 1-year low of $5.56 and a 1-year high of $28.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.95 and a quick ratio of 0.66. The stock has a market capitalization of $485.54 million, a PE ratio of 7.64 and a beta of 0.74.
DPLO has been the subject of a number of recent research reports. Svb Leerink lowered Diplomat Pharmacy from an outperform rating to a market perform rating and lowered their target price for the company from $24.00 to $6.00 in a research note on Monday, February 25th. William Blair lowered Diplomat Pharmacy from a market perform rating to an underperform rating in a research note on Friday, February 22nd. TheStreet lowered Diplomat Pharmacy from a c- rating to a d+ rating in a research note on Monday, March 4th. ValuEngine lowered Diplomat Pharmacy from a sell rating to a strong sell rating in a research note on Monday, February 4th. Finally, Mizuho set a $8.00 target price on Diplomat Pharmacy and gave the company a hold rating in a research note on Friday, February 22nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. The company currently has a consensus rating of Hold and an average target price of $13.78.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Read More: What Are Treasury Bonds?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.